1. Home
  2. TENX vs EOD Comparison

TENX vs EOD Comparison

Compare TENX & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$14.82

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Logo Allspring Global Dividend Opportunity Fund of Beneficial Interest

EOD

Allspring Global Dividend Opportunity Fund of Beneficial Interest

HOLD

Current Price

$6.34

Market Cap

271.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
EOD
Founded
1967
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
317.8M
271.7M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
TENX
EOD
Price
$14.82
$6.34
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
1.3M
104.2K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
N/A
9.28%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.80
$5.48
52 Week High
$19.40
$6.74

Technical Indicators

Market Signals
Indicator
TENX
EOD
Relative Strength Index (RSI) 49.73 38.42
Support Level $13.13 $6.29
Resistance Level $16.35 $6.53
Average True Range (ATR) 1.20 0.11
MACD -0.22 -0.02
Stochastic Oscillator 19.95 9.38

Price Performance

Historical Comparison
TENX
EOD

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest

Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.

Share on Social Networks: